OncoWitan, Lille, Wasquehal, 59290, France(1).
Eur J Pharmacol. 2021 Jan 15;891:173735. doi: 10.1016/j.ejphar.2020.173735. Epub 2020 Nov 18.
The rhizome of the plant Atractylodes macrocephala Koidz is the major constituent of the Traditional Chinese Medicine Baizhu, frequently used to treat gastro-intestinal diseases. Many traditional medicine prescriptions based on Baizhu and the similar preparation Cangzhu are used in China, Korea and Japan as Qi-booster. These preparations contain atractylenolides, a small group of sesquiterpenoids endowed with antioxidant and anti-inflammatory properties. Atractylenolides I, II and III also display significant anticancer properties, reviewed here. The capacity of AT-I/II/IIII to inhibit cell proliferation and to induce cancer cell death have been analyzed, together with their effects of angiogenesis, metastasis, cell differentiation and stemness. The immune-modulatory properties of ATs are discussed. AT-I has been tested clinically for the treatment of cancer-induced cachexia with encouraging results. ATs, alone or combined with cytotoxic drugs, could be useful to treat cancers or to reduce side effects of radio and chemotherapy. Several signaling pathways have been implicated in their multi-targeted mechanisms of action, in particular those involving the central regulators TLR4, NFκB and Nrf2. A drug-induced reduction of inflammatory cytokines production (TNFα, IL-6) also characterizes these molecules which are generally weakly cytotoxic and well tolerated in vivo. Inhibition of Janus kinases (notably JAK2 and JAK3 targeted by AT-I and AT-III, respectively) has been postulated. Information about their metabolism and toxicity are limited but the long-established traditional use of the Atractylodes and the diversity of anticancer effects reported with AT-I and AT-III should encourage further studies with these molecules and structurally related natural products.
植物白术的根茎是中药白术的主要成分,常用于治疗胃肠疾病。许多以白术和类似制剂苍术为基础的传统中药方剂在中国、韩国和日本被用作补气药。这些制剂含有倍半萜内酯,这是一组具有抗氧化和抗炎特性的倍半萜。倍半萜内酯 I、II 和 III 也具有显著的抗癌特性,本文对此进行了综述。分析了 AT-I/II/IIII 抑制细胞增殖和诱导癌细胞死亡的能力,以及它们对血管生成、转移、细胞分化和干性的影响。还讨论了 ATs 的免疫调节特性。AT-I 已在临床上用于治疗癌症引起的恶病质,结果令人鼓舞。ATs 单独或与细胞毒性药物联合使用,可用于治疗癌症或减少放化疗的副作用。几种信号通路已被牵涉到其多靶点作用机制中,特别是涉及到 TLR4、NFκB 和 Nrf2 等中央调节剂。这些分子的特征还包括药物诱导的炎症细胞因子(TNFα、IL-6)产生减少,它们通常具有较弱的细胞毒性,在体内耐受性良好。已经提出了抑制 Janus 激酶(特别是 JAK2 和 JAK3,分别被 AT-I 和 AT-III 靶向)的假说。关于它们的代谢和毒性的信息有限,但白术的长期传统使用以及与 AT-I 和 AT-III 相关的报道的多种抗癌作用应鼓励对这些分子和结构相关的天然产物进行进一步研究。